KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Receivables (2016 - 2025)

Astrana Health's Receivables history spans 15 years, with the latest figure at $391.1 million for Q3 2025.

  • For Q3 2025, Receivables rose 407.07% year-over-year to $391.1 million; the TTM value through Sep 2025 reached $391.1 million, up 407.07%, while the annual FY2024 figure was $305.5 million, 291.07% up from the prior year.
  • Receivables for Q3 2025 was $391.1 million at Astrana Health, up from $357.4 million in the prior quarter.
  • Across five years, Receivables topped out at $391.1 million in Q3 2025 and bottomed at $14.3 million in Q1 2022.
  • The 5-year median for Receivables is $83.3 million (2021), against an average of $120.3 million.
  • The largest YoY upside for Receivables was 957.56% in 2023 against a maximum downside of 83.81% in 2023.
  • A 5-year view of Receivables shows it stood at $80.0 million in 2021, then tumbled by 79.5% to $16.4 million in 2022, then surged by 376.43% to $78.1 million in 2023, then soared by 291.07% to $305.5 million in 2024, then increased by 28.03% to $391.1 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Receivables are $391.1 million (Q3 2025), $357.4 million (Q2 2025), and $69.8 million (Q1 2025).